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Abstract
Background: Colorectal cancer (CRC) is among the leading causes of cancer-related morbidity and mortality
worldwide. Despite clinical practice guidelines to guide surveillance care for those who have completed treatment
for this disease as well as screening for first degree relatives of people with CRC, the level of uptake of these
recommendations remains uncertain. If outcomes for both patients and their families are to be improved, it is
important to establish systematic and cost-effective interventions to improve adherence to guideline
recommendations for CRC surveillance and screening.
Methods/Design: A randomized controlled trial will be used to test the effectiveness of a print-based intervention
to improve adherence to colonoscopy surveillance among people with CRC and adherence to CRC screening
recommendations among their first degree relatives (FDRs). People diagnosed with CRC in the past 10 months will
be recruited through a population-based cancer registry. Consenting participants will be asked if their first degree
relatives might also be willing to participate in the trial. Information on family history of CRC will be obtained from
patients at baseline. Patients and their families will be randomized to either minimal ethical care or the print-based
intervention. The print-based intervention for FDRs will be tailored to the participant’s level of risk of CRC as
determined by the self-reported family history assessment. Follow up data on surveillance and screening
participation will be collected from patients and their FDRs respectively at 12, 24 and 36 months’ post recruitment.
The primary analyses will relate to comparing levels of guideline adherence in usual care group versus print-based
group in the patient sample and the FDR sample respectively.
Discussion: Results of this study will provide contribute to the evidence base about effective strategies to a)
improve adherence to surveillance recommendation for people with CRC; and b) improve adherence to screening
recommendation for FDRs of people with CRC. The use of a population-based cancer registry to access the target
population may have significant advantages in increasing the reach of the intervention.
Trial registration: This trial is registered with the Australian and New Zealand Clinical Trials Registry Registration
Number (ACTRN): ACTRN12609000628246.
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Colorectal cancer (CRC) is among the most prevalent
cancers worldwide and carries a substantial mortality
and morbidity burden [1]. Five year survival ranges
between 8% and 93%, depending on stage of disease [2].
Among people who have undergone surgical resection
for CRC, surveillance colonoscopy is recommended at
regular intervals to detect recurrence and metachronous
cancers. In Australia, the National Health and Medical
Research Council (NHMRC) clinical practice guidelines
recommend that colonoscopy is performed at the time
of diagnosis, or if this is not possible, within six months’
of surgery, and then at an interval of 3-5 years [3].
Although NHMRC guidelines [3] have been available for
some time, the level of uptake of the recommendations
is uncertain. Australian studies have indicated that
between 23%-38% of surveillance colonoscopies are in
line with NHMRC recommendations [4,5].
Screening of first degree relatives (FDRs) of patients
with colorectal cancer is widely recommended [6]. Evi-
dence for the benefits of screening of first degree relatives
of colorectal cancer patients come from prospective and
retrospective cohort studies [5,7-9] and from a non-ran-
domized study of relatives in a high risk familial setting,
where there was a reduction in mortality from colorectal
cancer in those accepting compared to those refusing
screening [1]. The type of screening and recommended
interval is dependent upon level of risk [3]. Current Aus-
tralian guidelines classify risk levels for FDRs as shown in
Table 1 [3]. Recommended screening for each of these
risk categories is as follows: Risk level 1: Faecal occult
blood testing every second year from age 50 years and
consider flexible sigmoidoscopy every 5 years. Risk level
2: Colonoscopy every 5 years starting at age 50 years or
at 10 years younger than the earliest age of first diagnosis
of bowel cancer in the family, whichever comes first.
Flexible sigmoidoscopy and double contrast barium
enema or CT colonography may be offered where colo-
noscopy is contraindicated. Risk level 3: Colonoscopy
every one or two years for families with proven Heredi-
tary Non-polyposis Colorectal Cancer (HNPCC) com-
mencing at 25 years or 5 years before the earliest age of
cancer diagnosis in the family, whichever comes first;
annual screening for proven gene carriers or clinically
affected members of Amsterdam-positive families.
While a small number of studies have attempted to
improve adherence to screening among FDRs [10], few
studies have evaluated the effectiveness of systematic
interventions which target care for both the person with
cancer and their FDRs. An improvement in guideline
adherence was demonstrated at a single site following dis-
semination of the guidelines to all specialists and imple-
mentation of a nurse co-ordinator role to ensure that
screening/surveillance recommendations matched guide-
line recommendations [4]. However, effective interven-
tions need to be developed that have the potential for
broad implementation and that enable follow up and
screening advice to be systematically and comprehensively
provided to all identified colorectal cancer patients and
their relatives, not just to those who present for care.
Therefore, the current study will seek to evaluate an inter-
vention which aims to improve screening/surveillance care
for both people with bowel cancer and their first degree
relatives using a population-based cancer registry as the
Table 1 Risk categories for colorectal cancer based on family history
Risk Category Characteristics
Category 1. At or slightly above
average risk
Asymptomatic people who have:
￿ no personal history of bowel cancer, advanced adenoma, or chronic ulcerative colitis, and
￿ either no close relatives with bowel cancer or one first-degree or second-degree relative with bowel cancer
diagnosed at age 55 years or older.
Category 2. Moderately increased
risk
Asymptomatic people who have:
￿ one first-degree relative with bowel cancer diagnosed before the age of 55 years (without the potentially high-
risk features listed below for category 3), or
￿ two first-degree or one first- and one second-degree relative(s) on the same side of the family with bowel
cancer diagnosed at any age (without the potentially high-risk features listed below for category 3).
Category 3. Potentially high risk Asymptomatic people who have:
￿ three or more first-degree or a combination of first-degree and second-degree relatives on the
same side of the family diagnosed with bowel cancer (suspected HNPCC), or
￿ two or more first-degree or second-degree relatives on the same side of the family diagnosed with bowel
cancer, including any of the following high-risk features:
- multiple bowel cancers in the one person
- bowel cancer before the age of 50 years
- at least one relative with cancer of the endometrium, ovary, stomach, small bowel, renal pelvis, ureter, biliary
tract or brain, or at least one first-degree relative with a large number of adenomas throughout the large bowel
(suspected FAP), or
￿ somebody in the family in whom the presence of a high-risk mutation in the APC (adenomatous polyposis
coli) gene or one of the mismatch repair (MMR) genes has been identified.
￿ The above definitions are based on the National Health and Medical Research Council’s clinical practice guidelines [3].
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tests an intervention capable of having an impact on the
entire affected population [11].
Aims
The aims of this trial will be to:
i. Test the effectiveness of tailored print-based inter-
vention to improve a) adherence to surveillance colono-
scopy recommendations for people with bowel cancer b)
adherence to bowel cancer screening guidelines among
their first degree relatives.
ii. Examine how the identified cancer patients’ and
first degree relatives’ socio-demographic characteristics,
disease characteristics (for index case), risk category (for
first degree relatives), intervention groups and providers’
characteristics influence whether or not: a) colorectal
cancer patients; and b) first degree relatives of colorectal
cancer patients, are appropriately screened.
iii. Undertake a cost-effectiveness analysis of the
intervention strategy by comparing the differential cost
of an intervention and usual care conditions by
changes in the quality-adjusted life years associated
with each intervention.
Methods/Design
Ethics approvals
Full ethical approval for this study has been obtained
from the Cancer Council Victoria Human Research
Ethics Committee and the University of Newcastle
Human Research Ethics Committee.
Setting
People with a diagnosis of bowel cancer within the last
10 months will be recruited from population-based can-
cer Victorian Cancer Registry covering the entire
Australian state of Victoria (population 5.5 million).
Patient eligibility and recruitment
People with bowel cancer (index cases) who meet the
following criteria will be identified from the cancer reg-
istry: 1) aged 18 or older; 2) registered with cancer reg-
istry within 10 months of diagnosis. The registry will
write to the notifying doctor of each potentially eligible
person and ask the doctor to contact the registry within
4 weeks if there is any reason why the patient should
not be contacted about the study. Index cases whose
doctors perceive them to be unsuitable for the study
will be excluded. The registry will contact remaining
index cases and ask their permission to pass their con-
tact details onto the research team. Two reminders will
be sent to non responders. Those who consent will be
invited to participate in the trial with two reminders
sent to non responders.
Assessment of family history
Patients will complete a baseline computer assisted tele-
phone interview (CATI) to assess family history. On the
basis of their report of family history each index case and
their family will be classified as 1) average risk; 2)
increased risk or 3) potentially high risk. These cate-
gories, defined according to the definition of the National
Health and Medical Research Council (NHMRC), are
each associated with different types of screening recom-
mendations. Participants will also complete questions on
age, gender, marital status, education and employment,
disease characteristics, treatment, screening history, sur-
veillance intentions and quality of life. Quality of life will
be assessed using the European Quality of Life Scale
(EQ-5D version) which covers 5 dimensions of health:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression [12].
FDR eligibility
First degree relatives of people with bowel cancer will be
eligible to participate in the trial if they are a) aged 18
or older; b) English speaking; and c) able to provide
informed consent. Those with a prior diagnosis of bowel
cancer, Crohn’s disease, or inflammatory bowel disease
will be ineligible.
Recruitment of FDRs
Patients will be asked to provide the names and contact
details of any living first degree relatives aged 18 or older.
They will be asked to indicate which (if any) of their
FDRs they are willing for the research team to contact
about the study. A choice will be given regarding method
of contact of FDRs. Option one will involve the patient
being given a letter about the study which they can pass
onto their relatives; while option 2 will involve the
research team contacting the relative(s) directly by mail.
Patients will be asked to seek their relatives’ permission
prior to selecting the latter option. Non responders for
option one receive one reminder letter. The information
pack will contain a cover letter, information statement
about the study, and ask the person to contact the
research team if they were interested in participating. If
the index case has provided the relative’s phone number,
the letter will ask the relative to return a “do not contact”
f o r mw i t h i nt h en e x tt w ow e e k si ft h e yd i dn o tw a n ta
researcher to contact them about the study. FDRs that
consent to being contacted will be telephoned and asked
to participate in a brief screening interview to assess trial
eligibility. Consenting eligible FDRs will complete a base-
line computer-assisted telephone interview (CATI) which
will include questions about age, gender, marital status,
education, employment, knowledge about screening and
prior screening history and future intentions of
Carey et al. BMC Cancer 2012, 12:62
http://www.biomedcentral.com/1471-2407/12/62
Page 3 of 5screening, use of complementary therapies, and quality of
l i f e .Q u a l i t yo fl i f ew i l lb ea s s e s s e du s i n gt h eE u r o p e a n
Quality of Life Scale [12].
Randomization
Consenting patients and their first degree relatives will
be randomized as a family unit to either “minimal ethi-
cal care” or a tailored print based intervention. Rando-
mization will be conducted centrally using a computer
generated procedure. Interviewers will be blind to parti-
cipants’ allocation.
Intervention
Patients assigned to the intervention group will receive a
letter detailing recommendations for follow up care. A fact
sheet with information about recommended follow up care
will be mailed to patients. The patient’s GP and surgeon
will also be sent a fact sheet with information about best
evidence surveillance care. First degree relatives will receive
a tailored letter which provides advice on recommended
bowel cancer screening tests and intervals based on their
level of family risk. A brochure detailing the three risk
levels and their corresponding screening recommendations
will be enclosed. Family risk will be determined based on
patient self report information and will correspond to the
three levels of risk identified in the National Health and
Medical Research Guidelines. The GP of the FDR will also
receive a tailored letter indicating the likely risk category of
the first degree relative. A brochure detailing screening
recommendations for each risk category will be enclosed.
Minimal ethical care
Patients and first degree relatives assigned to the minimal
ethical care group will receive a generic booklet on bowel
cancer and generic pamphlet on bowel cancer screening
respectively. First degree relatives categorized at very high
risk will sent the tailored information as per the interven-
tion group as part of our duty of care.
Follow up assessments
Both first degree relatives and patients will be mailed fol-
low up surveys at 12, 24 and 36 months. First degree rela-
tives will be asked to provide self report information on
the type of bowel cancer screening undertaken in the past
12 months (if any), and any days off work due screening.
Patients will be asked to provide self report information
about participation in surveillance colonoscopy within the
past 12 months, quality of life. Patients or first degree rela-
tives who report having had a colonoscopy or bowel can-
cer screening test in the past 12 months will be asked for
permission to contact their doctor to verify the timing and
results of the test. A random sample of 10% of self
reported screening will be verified in this way to determine
accuracy of self reported screening behavior.
Statistical analysis
Baseline characteristics of index patients and first degree
relatives will be reported for intervention and control
groups. Aim 1. The proportion of index patients and the
proportion of first degree relatives who undertake screen-
ing/surveillance tests in line with NHMRC recommenda-
tions for their risk category in years 1, 2 and 3 following
diagnosis in the index case will be compared between the
two experimental groups using the chi-square test. Aim 2.
Sociodemographic characteristics, screening history, risk
status, concurrent engagement in alternative programs of
surveillance and symptom status, of those who are appro-
priately and inappropriately screened at each time point
will be compared using the chi-square test for categorical
variables and the t-test or a non-parametric equivalent for
continuous variables. Logistic regression will then be used
to examine factors associated with appropriate screening/
surveillance while adjusting for potential confounders.
Variables will be included in the initial logistic model if
they have a p value of 0.2 or less on univariate analyses,
with backward stepwise methods used to exclude variables
with a p value of 0.10 or more on the likelihood ratio test.
Analysis will be undertaken separately for the index cases
and for first degree relatives. Analyses will be adjusted for
clustering of relatives within index patients using General-
ised Estimating Equations.
Sample size
Approximately 3000 eligible new cases of colorectal cancer
are expected to be identified through the Victorian Cancer
Registry each year. Based on previous experience, 3% of
clinicians will refuse permission for their patient to be
approached, therefore we expect permission to contact
2900. Based on prior research, we expect 60% of patients
contacted by the VCR agree to be contacted by the
research team and 70% of these consent to participate in
the study. Recruitment will be undertaken for 12 months,
thus 1200 index cases will be recruited in total, or 600 per
group. Aim 1. Assuming that 20% of participants will be
lost at each follow-up time (leaving 480, 380, 300 index
cases per group available at 12, 24, 36 month), the study
will have 80% power, with a 5% significance level, to detect
ad i f f e r e n c eo f1 0 %b e t w e e ne x p e r i m e n t a lg r o u p si nt h e
proportion of index cases appropriately surveillance at 12
month follow-up, 12% difference at 24 and 36 month fol-
low-up. It is estimated that t h e r ew i l lb ea na v e r a g eo f2
eligible first degree relatives for each index case, and that
70% of these will consent and be available for 12 month
follow-up, with a 20% loss to follow-up at each of the
remaining assessment times. This will provide 1680, 1350
and 1050 relatives at 12, 24 and 36 months. Allowing for a
design effect of 2 will provide an effective sample size of
400, 330 and 260 per group at each time point, which is
adequate to detect a 10% difference in the proportion of
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12% at 24 months and 13% at 36 months with 5% signifi-
cance level and 80-85% power. A 10% difference at the
first follow-up is considered to be clinically meaningful,
given the burden of disease from colorectal cancer and the
intervention effect is anticipated to increase over time, as
the intervention will continue for the three year follow-up
period. Aim 2. Assuming at least one third of individuals
will be appropriately screened at each follow up time, the
study will also have at least 80% power to detect differ-
ences in characteristics of those who are and are not fol-
lowed up/screened appropriately of 10-13% for binary
variables and 0.2-0.25 standard deviations for continuous
variables for index cases, and 11-14% for binary variables
and 0.22 -0.27 standard deviations for continuous variables
for FDRs.
Cost effectiveness analysis
The cost-effectiveness analysis will examine the null
hypothesis that the mean cost-effectiveness of the pro-
posed health care intervention is no different to the
mean cost-effectiveness of usual care. The perspective
adopted for this analysis is societal and will encapsulate
the viewpoint of the health sector in which resources
associated with the provision of care (i.e., colorectal
screening) are combined with cost-savings arising from
that care, and the viewpoint of the patient in terms of
out of pocket expenditures associated with treatment.
Costs will then be compared with changes in patients’
quality adjusted life years.
Time line for the study
Recruitment to the trial began in 2010 and is expected
to be completed in early 2012.
Discussion
In order to improve health outcomes across a range of
areas, there is an urgent need to find effective strategies
for improving uptake of and adherence to evidence-
based guidelines. Results of this study will provide con-
tribute to the evidence base about effective strategies to
a) improve adherence to surveillance recommendation
for people with CRC; and b) improve adherence to
screening recommendation for FDRs of people with
CRC. The use of a population-based cancer registry to
access the target population may have significant advan-
tages for increasing the reach of the intervention. If the
intervention is found to be effective there is scope for it
to be replicated in other population-based cancer
registries.
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